Boundless Bio, Inc. Files Amendment to Registration Statement

Ticker: BOLD · Form: S-1/A · Filed: Mar 21, 2024 · CIK: 1782303

Boundless Bio, INC. S-1/A Filing Summary
FieldDetail
CompanyBoundless Bio, INC. (BOLD)
Form TypeS-1/A
Filed DateMar 21, 2024
Risk Levellow
Pages15
Reading Time18 min
Key Dollar Amounts$15.00, $17.00, $252.1 million
Sentimentneutral

Sentiment: neutral

Topics: S-1/A, Registration Statement, Boundless Bio, SEC Filing, IPO

TL;DR

<b>Boundless Bio, Inc. has filed an amendment to its S-1 registration statement, indicating ongoing preparations for a public offering.</b>

AI Summary

Boundless Bio, Inc. (BOLD) filed a Amended IPO Registration (S-1/A) with the SEC on March 21, 2024. Boundless Bio, Inc. filed an S-1/A (Amendment No. 1) with the SEC on March 21, 2024. The company is incorporated in Delaware and its principal executive offices are located in San Diego, CA. The filing relates to a registration statement under the Securities Act of 1933. Boundless Bio, Inc. is classified under the SIC code 2834 (Pharmaceutical Preparations). The filing indicates the company is a non-accelerated filer, smaller reporting company, and emerging growth company.

Why It Matters

For investors and stakeholders tracking Boundless Bio, Inc., this filing contains several important signals. This amendment signifies Boundless Bio's continued progress towards becoming a publicly traded company, which could provide access to significant capital for its operations and research. As an emerging growth company and smaller reporting company, Boundless Bio may benefit from certain regulatory accommodations, potentially impacting its reporting requirements and compliance costs.

Risk Assessment

Risk Level: low — Boundless Bio, Inc. shows low risk based on this filing. The filing is an amendment to a registration statement, indicating procedural steps rather than new material business developments or financial performance, thus posing low immediate risk.

Analyst Insight

Monitor future filings for details on the proposed offering, including share price, number of shares, and use of proceeds, to assess investment potential.

Key Numbers

Key Players & Entities

FAQ

When did Boundless Bio, Inc. file this S-1/A?

Boundless Bio, Inc. filed this Amended IPO Registration (S-1/A) with the SEC on March 21, 2024.

What is a S-1/A filing?

A S-1/A is a amendment to an IPO registration statement, typically incorporating SEC feedback. This particular S-1/A was filed by Boundless Bio, Inc. (BOLD).

Where can I read the original S-1/A filing from Boundless Bio, Inc.?

You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by Boundless Bio, Inc..

What are the key takeaways from Boundless Bio, Inc.'s S-1/A?

Boundless Bio, Inc. filed this S-1/A on March 21, 2024. Key takeaways: Boundless Bio, Inc. filed an S-1/A (Amendment No. 1) with the SEC on March 21, 2024.. The company is incorporated in Delaware and its principal executive offices are located in San Diego, CA.. The filing relates to a registration statement under the Securities Act of 1933..

Is Boundless Bio, Inc. a risky investment based on this filing?

Based on this S-1/A, Boundless Bio, Inc. presents a relatively low-risk profile. The filing is an amendment to a registration statement, indicating procedural steps rather than new material business developments or financial performance, thus posing low immediate risk.

What should investors do after reading Boundless Bio, Inc.'s S-1/A?

Monitor future filings for details on the proposed offering, including share price, number of shares, and use of proceeds, to assess investment potential. The overall sentiment from this filing is neutral.

How does Boundless Bio, Inc. compare to its industry peers?

Boundless Bio operates in the pharmaceutical preparations industry, focusing on the development of novel therapeutics.

Are there regulatory concerns for Boundless Bio, Inc.?

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

Industry Context

Boundless Bio operates in the pharmaceutical preparations industry, focusing on the development of novel therapeutics.

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities offerings in the United States.

What Investors Should Do

  1. Review the full S-1/A filing for detailed business descriptions and risk factors.
  2. Track subsequent SEC filings for updates on the company's IPO status and financial performance.
  3. Research the company's therapeutic pipeline and target markets.

Key Dates

Year-Over-Year Comparison

This is Amendment No. 1 to the S-1 registration statement, indicating a revision or addition to the initial filing.

Filing Stats: 4,456 words · 18 min read · ~15 pages · Grade level 15.4 · Accepted 2024-03-21 06:04:59

Key Financial Figures

Filing Documents

Risk Factors

Risk Factors 14 Special Note Regarding Forward-Looking Statements 77 Market and Industry Data 78

Use of Proceeds

Use of Proceeds 79 Dividend Policy 81 Capitalization 82

Managements Discussion and Analysis of Financial Condition and Results of Operations

Managements Discussion and Analysis of Financial Condition and Results of Operations 87

Business

Business 101 Management 165 Executive and Director Compensation 175 Certain Relationships and Related Person Transactions 194 Principal Stockholders 197

Description of Capital Stock

Description of Capital Stock 200 Shares Eligible For Future Sale 206 Material United States Federal Income Tax Consequences to Non-U.S. Holders 209

Underwriting

Underwriting 214 Legal Matters 221 Experts 221 Where You Can Find More Information 221 Index to Financial Statements F-1 Through and including , 2024 (the 25th day after the date of this prospectus), all dealers that buy, sell or trade shares of our common stock, whether or not participating in this offering, may be required to deliver a prospectus. This delivery requirement is in addition to the dealers obligation to deliver a prospectus when acting as an underwriter and with respect to an unsold allotment or subscription. Neither we nor the underwriters have authorized anyone to provide you with information other than that contained in this prospectus or any free writing prospectus prepared by or on behalf of us or to which we have referred you. We and the underwriters take no responsibility for, and can provide no assurance as to, the reliability of, any other information that others may give you. We and the underwriters are offering to sell, and seeking offers to buy, shares of our common stock only in jurisdictions where offers and sales are permitted. The information contained in this prospectus or any free writing prospectus is accurate only as of its date, regardless of its time of delivery or of any sale of shares of our common stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside of the United States: we have not, and the underwriters have not, done anything that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside of the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the shares of our common stock and the distribution of this prospectus outside of the United States. i Table of Contents PROSPECTUS SUMMARY This summar

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing